Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic
compound, administered intranasally for the management of acute anxiety in patients diagnosed
with generalized social phobia.